Enrique Grande, Director of the Medical Oncology Department at Quirónsalud, and Adjunct Professor at The University of Texas MD Anderson Cancer Center, shared a post on X:
“IMvigor011 at ASCO26: ctDNA-guided adjuvant atezolizumab in MIBC improved DFS and OS in ctDNA+ patients – with no negative impact on patient-reported QoL.
>90% of patients reported little or no treatment side-effect burden throughout therapy.
Efficacy and tolerability together. Relevant for shared decision-making in the adjuvant setting.”
Article: Patient-reported outcomes from IMvigor011: A phase 3 study of circulating tumor (ct)DNA–guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer (MIBC).
Author: Joaquim Bellmunt
Other articles featuring Enrique Grande on OncoDaily.